Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients
about
Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapyChanges in clearance, volume and bioavailability of immunosuppressants when given with HAART in HIV-1 infected liver and kidney transplant recipients.Can therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents?Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir.Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir.Impact of body weight and missed doses on lopinavir concentrations with standard and increased lopinavir/ritonavir doses during late pregnancy.Lopinavir/ritonavir population pharmacokinetics in neonates and infants.Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 yearsAssessment of lopinavir pharmacokinetics with respect to developmental changes in infants and the impact on weight band-based dosing.No Need for Lopinavir Dose Adjustment during Pregnancy: a Population Pharmacokinetic and Exposure-Response Analysis in Pregnant and Nonpregnant HIV-Infected Subjects.Population-based assessments of clinical drug-drug interactions: qualitative indices or quantitative measures?ADME pathway approach for pharmacogenetic studies of anti-HIV therapy.Clinical pharmacokinetics of antiretroviral drugs in older persons.Population pharmacokinetics of lopinavir predict suboptimal therapeutic concentrations in treatment-experienced human immunodeficiency virus-infected children.Factors influencing lopinavir and atazanavir plasma concentration.Integrated population pharmacokinetic/viral dynamic modelling of lopinavir/ritonavir in HIV-1 treatment-naïve patients.Safety of pharmacoenhancers for HIV therapy.Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus.Plasma trough concentrations of darunavir/ritonavir and raltegravir in older patients with HIV-1 infection.Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients.Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir.Importance of characterizing determinants of variability in exposure: application to dasatinib in subjects with chronic myeloid leukemia.Population Pharmacokinetics of Lopinavir in Severely Malnourished HIV Infected Children and the Effect on Treatment Outcomes.
P2860
Q26771182-C507F7B8-71E8-4464-9741-E1C6B008D5F3Q33599107-16CC10AB-DB93-4048-ACF4-B15EC1A49CABQ33914723-D1E29BD1-0ED2-4A4A-8F2F-F1B367DC4E45Q34100187-872CC54B-AD2E-41CE-AFC8-750697A276DBQ34677780-0BACC256-A3F5-4C59-9990-0A5398DBA97BQ34710705-680D50BE-C0E0-416E-8FA7-6E77C797A1A5Q34996974-10D79A1A-5B20-423A-BB6C-F8BE1C821CFEQ35127775-96896EC0-A724-4255-99B7-3087AF424FA4Q35973937-7E06BF03-06C0-457B-9ECC-29E6D1B2A56AQ36439051-F7F22668-8479-4607-8961-75623FF51F37Q36628026-1A493423-81B7-4834-963E-28464F57264FQ36845126-BC53ECCD-A644-47F1-BED1-DC76414A190EQ36905884-DB3EE86D-B433-46D4-BAAF-989B1AF3B8BAQ37204267-FFBFEC5B-C7CA-4175-83B3-85B621566972Q37476403-A8CB9B7C-D307-4479-AF58-7E822E82DEE6Q37656345-0EA75D3F-7F6A-43A0-BE74-2C4CAFDADDF5Q38057371-259A68D4-EDAD-42A2-B6E9-6D3ABE3B5754Q40118824-618CF360-DB15-481A-A4D2-F1DA4EA88244Q40360498-EC23D9CD-D3A4-442C-9A87-653DDC702167Q41333285-3C1B270E-90BA-4E89-919D-2AC3179D1C35Q42429561-4125E743-B153-400C-8115-761178467782Q46380705-69F22FB1-876C-4B18-BD78-E45629BD4D8AQ49949305-A60E7222-7BAF-46D0-86C5-F0C6FEBC6346
P2860
Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Population pharmacokinetics of ...... vir in HIV-1-infected patients
@ast
Population pharmacokinetics of ...... vir in HIV-1-infected patients
@en
type
label
Population pharmacokinetics of ...... vir in HIV-1-infected patients
@ast
Population pharmacokinetics of ...... vir in HIV-1-infected patients
@en
prefLabel
Population pharmacokinetics of ...... vir in HIV-1-infected patients
@ast
Population pharmacokinetics of ...... vir in HIV-1-infected patients
@en
P2093
P2860
P1476
Population pharmacokinetics of ...... vir in HIV-1-infected patients
@en
P2093
A D R Huitema
A T A Mairuhu
B S Kappelhoff
E C M van Gorp
J H Beijnen
J W Mulder
K M L Crommentuyn
P L Meenhorst
P2860
P304
P356
10.1111/J.1365-2125.2005.02455.X
P407
P577
2005-10-01T00:00:00Z